Global Collaboration SalubrisBio is an innovation-focused biotech with global aspirations, headquartered in the US and backed by a larger China-based Salubris ecosystem. Opportunity: propose partnerships or joint development programs with their US presence and China-origin backing to accelerate global biologics programs.

Biologic Focus The company concentrates on discovery and development of novel biologics, including antibody-drug conjugates and fusion proteins. Opportunity: offer specialized CRO/CMO services, assay development, and translational research support tailored to complex biologics pipelines.

Strategic Capital SalubrisBio has secured substantial funding ($32M in 2022 and total funding around $102M) and revenue in the lower tens of millions, signaling readiness to scale. Opportunity: present service packages for late-stage development, manufacturing scale-up, and international regulatory support to accelerate clinical programs.

Pipeline Partnerships Past collaborations include Viracta and a heart failure antibody fusion program (JK07), indicating openness to strategic alliances with biotech and pharma players. Opportunity: explore licensing, co-development, or research collaborations around JK06 or JK07-like programs or related biologics assets.

Scale and Capacity Access to GeneKey Biotech resources and manufacturing capacity up to 2000L, plus a workforce of seasoned scientists, provides a foundation for early-phase to mid-scale production. Opportunity: propose pilot manufacturing, process development, and tech transfer services to de-risk scale-up for biologics candidates.